Protein kinase Pim-1 has been implicated in the development of hematopoietic and prostatic malignancies. Here, we present the evidence that two isoforms, the 44 and 33 kDa Pim-1, are expressed in all human prostate cancer cell lines examined. The subcellular localization of human 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus in PCA cells. The 44 kDa Pim-1 contains the proline-rich motif at the N-terminus and directly binds to the SH3 domain of tyrosine kinase Etk. Such interaction leads to the activation of Etk kinase activity possibly by competing with the tumor suppressor p53. This is corroborated by the fact that overexpression of the 44 kDa Pim-1 in prostate cancer cells confers the resistance to chemotherapeutic drugs. Our results suggest that these two isoforms of Pim-1 kinase may regulate distinct substrates and the 44 kDa Pim-1 may play a more prominent role in drug resistance in prostate cancer cells.
Introduction
The serine/threonine kinase Pim-1 was originally identified as a frequently activated cellular proto-oncogene by retrovirus insertion in mice (Cuypers et al., 1984) . Human pim-1 gene is mapped to the fragile chromosomal site 6p21 where the aberrant translocations were reported in acute nonlymphocytic leukemia (von Lindern et al., 1989) . The levels of pim-1 mRNA are often elevated in human leukemias (Amson et al., 1989) . The transgenic mice overexpressing the pim-1 gene are tumor prone and susceptible to carcinogens and other tumor promoters, suggesting a direct role of Pim-1 kinase in oncogenesis (Breuer et al., 1989; van Lohuizen et al., 1989) . Pim-1 has been implicated in the regulation of cell cycle and transcription by phosphorylating a number of substrates such as cdc25A, HP1 and p100 (Leverson et al., 1998; Mochizuki et al., 1999; Koike et al., 2000; Zhao et al., 2001) . Increasing evidence suggests that Pim-1 may play a role in the regulation of the survival signaling by phosphorylating BAD (Yan et al., 2003; Aho et al., 2004) .
Murine pim-1 gene encodes two proteins with molecular weight 33 and 44 kDa by utilizing two alternative translation initiation sites (Saris et al., 1991) . The translation of the 44 kDa Pim-1 was reported to initiate at a nonconventional start codon CUG in mouse, while the 33 kDa isoform is translated from a downstream AUG. It has yet to be determined whether regulation of Pim-1 kinase by the alternative translation initiation is conserved in human cells as well. Our current knowledge about Pim-1 kinase is largely derived from the studies on the 33 kDa isoform Pim-1. Several potential substrates for Pim-1, including p100, cdc25A, HP1 and TFAF2/SNX6, have been identified through various genetic screenings (Leverson et al., 1998; Mochizuki et al., 1999; Koike et al., 2000; Ishibashi et al., 2001; Zhao et al., 2001) .
Recently, Pim-1 has emerged as a potential diagnostic marker in prostate cancer (Dhanasekaran et al., 2001) . It has been shown that Pim-1 is frequently upregulated in human prostate cancers as well as in the prostate tumor tissues from various mouse models (Ellwood-Yen et al., 2003; Wang et al., 2003; Valdman et al., 2004) , strongly suggesting a potential role of Pim-1 in prostate cancer development and progression. However, very little is known about the functions of Pim-1 in prostate cancer cells. Recently, we have showed that Pim-1 kinase is regulated by IL6 in prostate cancer cells and involved in IL6-induced ligand-independent activation of the androgen receptor (Kim et al., 2004) . We also demonstrated that the 33 kDa Pim-1 and the Tec family tyrosine kinase Etk can act synergistically to promote the androgen receptor-mediated transcriptional activity in prostate cancer cells. Furthermore, in an SH3 domain array screening for the ligands of the p53, proline-rich domain, the Tec family kinases were identified as the potential targets for p53 . Upon treatment of prostate cancer cells with chemotherapeutic drugs, p53 binds to Etk through an interaction between the SH3 domain of Etk and the proline-rich domain of p53 which leads to inactivation of Etk tyrosine kinase activity. Downregulation of Etk kinase activity appears to be required for p53-induced apoptosis. In this report, we demonstrate that the 44 kDa isoform Pim-1L contains a proline-rich motif and interacts directly with tyrosine kinase Etk through an interaction between the PXXP motif and the SH3 domain of Etk. Such interaction competes with the tumor suppressor p53 for binding to Etk and activates Etk kinase activity. The localization of the 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus, suggesting that these two isoforms may regulate distinct substrates in PCA cells. Our results suggest that Pim-1L may play a more prominent role in antiapoptosis signaling in response to chemotherapeutic drugs.
Results
We previously showed that the expression of Pim-1 is upregulated in IL6-treated LNCaP cells (Kim et al., 2004) . In addition to the doublet bands corresponding to the previously reported p33 kDa Pim-1, a protein with higher molecular weight around 40 kDa (marker) is also induced by IL 6 and reactive with the monoclonal anti-Pim-1 antibody (Figure 1a) . A similar pattern was observed in PC3 cells in which an IL 6 autocrine loop is present and the treatment of a neutralizing anti-IL6 antibody dramatically suppressed the expression of both the 33 kDa and the 40 kDa proteins (Figure 1b) . Since it was reported that a 44 kDa isoform of Pim-1 is encoded in mouse cells as a result from the usage of an alternative start codon (Saris et al., 1991) , we included the 293T cell transfected by an EST clone, in which the human Pim-1 cDNA sequence was under the control of the CMV promoter, as a control. This EST clone can produce two major forms of Pim-1, namely the 33 and 44 kDa forms in 293T cells. It is noticeable that the EST-derived 44 kDa protein had a slower mobility in comparison to that of the IL6-regulated endogenous Pim-1 isoform around the 40kDa marker. To test whether the mobility shift is due to phosphorylation resulted from overexpression of the kinase, we treated the EST-transfected cell lysate with alkaline phosphatase and increased the mobility of the 44 kDa Pim-1. Furthermore, we trans- Direct association of the p44 Pim-1 with Etk Y Xie et al fected prostate cancer cell lines with two independent human EST clones. As shown in Figure 1d , two major isoforms of Pim-1 proteins were expressed in all three prostate cancer cell lines tested. In both LNCaP and 22Rv1 cells, the 33 kDa Pim-1 was the predominant isoform, while in PC3 cells, the 44 and 33 kDa isoforms were expressed at similar levels. Sequencing of these two EST clones revealed the coding sequence of human Pim-1 shares high homology with the mouse 44 kDa Pim-1. Like the mouse 44 kDa Pim-1, a leucine residue is used as an alternative translation start site (Figure 1e) . Interestingly, three PXXP motifs are identified in the sequence, which is unique for the 44 kDa Pim-1L (Figure 1f ), suggesting that this region could potentially interact with the SH3-domain-containing proteins. To confirm that the 44 kDa isoform Pim-1 is indeed expressed in prostate cancer cells, a polyclonal antibody specifically recognizing the sequence of the first 92 amino acids that are exclusively present in the 44 kDa isoform was developed. Figure 2a shows that the antiPim-1L can only detect the transfected Flag-tagged 44 kDa Pim-1 (Pim-1L) but not the 33 kDa isoform (Pim-1S), since the epitopes recognized by this antibody are missing in Pim-1S. As shown in Figure 2b , Pim-1L is detectable in all four prostate cancer cell lines tested. It appeared that one additional band at a lower molecular weight could be detected in LNCaP by this antibody, which might result from the proteolytic cleavage or alternative splicing. This antibody could also detect the large isoform of Pim-1 encoded by the EST clone, although the mobility of the EST-derived Pim-1L was slower than that of the endogenous Pim-1L, possibly due to hyperphosphorylation resulted from overexpression as shown in Figure 1c . The presence of Pim-1L in human prostate cancer tissues was also confirmed by immunohistochemical staining of a tissue array. As summarized in Table 1 , both intensity and extent of Pim-1L staining are significantly higher in tumor tissue specimens than that in the benign prostate hyperplasia (BPH) controls. A representative field of the tissue array was shown in Figure 2c . In most of BPH tissues, very little of Pim-1L was detected in luminal epithelial cells, although weak staining in the nucleus of basal cells was observed. In the tumor tissues, Pim-1L was detected in many luminal cells with intensive staining in the cytoplasm as well as the plasma membrane.
We also examined the localization of Flag-tagged Pim-1L and Pim-1S in LNCaP cells. As shown in Figure 3a , despite that both isoforms are detectable in cytosol, the Flag-tagged Pim-1L is primarily localized on the plasma membrane, while the Pim-1S is predominantly present in the nucleus as reported previously (Ishibashi et al., 2001; Wang et al., 2002) . The Pim-1L is colocalized on the plasma membrane with Etk, which is known to be recruited to the plasma membrane upon activation (Chen et al., 2001) (Figure 3b ).
Given that Etk has an SH3 domain and Pim-1L has the PXXP motif, we tested whether these two proteins could interact with each other. As shown in Figure 4a , Pim-1L was co-immunoprecipitated with Etk in both COS-1 and 22Rv1 cells, while Pim-1S was barely detectable in the anti-Etk immunoprecipitates. The association of Pim-1L with Etk was accompanied with the robust increase of tyrosine phosphorylation of Etk. The interaction between Pim-1 and Etk was also detected in both cell lines (Figure 4a ). To investigate whether their association is mediated by the interaction between the SH3 domain of Etk and the PXXP motif in the Pim-1L, a series of deletion mutants of Etk were cotransfected with the Flag-tagged Pim-1L. As shown in Figure 4b , the deletion of the SH3 domain, of Etk abolished the interaction of the two proteins. Furthermore, to test whether the association between Etk and Pim-1L is direct, the GST-pull-down experiments were carried out by incubating the immobilized GST-SH3 Figure 2 Expression of the 44 kDa Pim-1 isoform in prostate cancer cells. (a) Specificity of the anti-Pim-1L antibody. The rabbit polyclonal antibody specific for the 44 kDa Pim-1 (Pim-1L) was developed as described in the Materials and methods section. The specificity of this antibody was determined by the immunoblotting analysis on the total cell lysates from the cells transfected with Flag-tagged Pim-1L or Pim-1S. The anti-Flag antibody was used to serve as a positive control. (b) Expression of Pim-1L in human prostate cancer cell lines. The total cell lysates from CWR-R1 (R1), LNCaP, PC3 and 22Rv1 cells were subjected to immunoblotting with anti-Pim-1L. The PC3 cells transfected with the EST clone was used as a control. The monoclonal antibody (aPim-1) for both isoforms was also used as a control. Anti-actin was used as a loading control. (c) Expression of Pim-1L is upregulated in human prostate tumor tissues. The prostate tissue array was subjected to IHC staining by using anti-Pim-1L as described in the Materials and methods section. The representative field of the array was shown.
Direct association of the p44 Pim-1 with Etk Y Xie et al fusion protein with the cell lysates expressing full-length Flag-tagged Pim-1L, the mutant with the deletion (Pim-1LDP) or mutation (Pim-1LPA) of both PXXP motifs. Only the Pim-1L was detected to associate with GST-SH3 domain while both mutants failed to bind (Figure 4c ), suggesting that the integrity of the PXXP motifs is required for the interaction between Pim-1L and Etk. The interaction between endogenous Etk and Pim-1L was also confirmed in two prostate cancer cell lines LNCaP and PC3 (Figure 4d ). The effects of Pim-1L on endogenous Etk activity in HUVEC and LNCaP cells were examined. Figure 4e shows that the ectopic expression of Pim-1L in both cell types resulted in the elevated tyrosine phosphorylation of endogenous Etk and STAT3. Since it is known that activation of Etk in these cells can induce tyrosine phosphorylation of Y705 in STAT3 , it is likely that Etk kinase activity is increased by Pim-1L but not by the mutant Pim-1LDP. This is further supported by the following in vitro kinase assays of Etk. As shown in Figure 4f , coexpression of Etk with Pim-1L but not the kinaseinactive mutant Pim-1LKM can enhance the kinase activity of Etk evidenced by the increased tyrosine phosphorylation of the exogenous substrate Gab1. Deletion of the proline-rich motifs of Pim-1L (Pim-1LDP) dramatically diminished its effects on the Etk kinase activity. Taken together, our data suggest that the integrity of both the SH3 domain of Etk and the proline-rich region of Pim-1L is required for the direct interaction of these two proteins and subsequent activation of Etk kinase activity by Pim-1L. It was shown that increase of Etk activity confers the drug resistance in LNCaP cells . We therefore examined the effects of Pim-1 on the drug response in LNCaP cells by infecting the cells with the lentiviruses expressing Pim-1L, Pim-1S, Pim-1LKM or the empty vector control. As shown in Figure 5a , treatment of LNCaP cells with doxorubicin induced rapid apoptosis as reported in our previous study. Approximately 50% of the cells expressing the empty vector or the kinase-inactive Pim-1LKM remained viable at 20 h post-treatment. The number of the survived cells in these two groups was drastically reduced to 20% after 40 h treatment. Overexpression of Pim-1S had some protection initially and kept about 80% of survival cells at 20 h; however, such protection was not able to sustain until 40 h. On the other hand, LNCaP cells expressing Pim-1L showed a remarkable resistance to the drug. Virtually no reduction on the cell viability was detected at 20 h post-treatment and more than 70% of the cells expressing Pim-1L remained viable after 40 h treatment. Thus, the ectopic expression of Pim-1L significantly protects LNCaP cells from doxorubicin-induced apoptosis, while Pim-1S only shows very limited protection. To test whether the protection by Pim-1L depends on Etk kinase activity, we coinfected LNCaP cells with Pim-1L and kinase-inactive EtkKQ simultaneously. Figure 5b shows that the kinase-inactive Etk significantly tampered the antiapoptosis effects of Pim-1L, suggesting that tyrosine kinase activity of Etk is required for the action of Pim-1L. Similar results were obtained when we tested the effects of Pim-1L on another chemotherapeutic drug, Mitoxantrone-induced apoptosis (Figure 5c and d) . It has been shown that the SH3 domain of Etk can interact with the proline-rich domain of p53 upon the cells are treated with doxorubicin and inhibition of Etk kinase activity Immunoflourescence staining by using anti-Flag antibody and the confocal imaging were carried out as described in the Materials and methods section. (b) Colocalization of Pim-1L and Etk. LNCaP cells were transfected with Flag-tagged Pim-1L and T7-Etk. At 48 h post-transfection, the cells were fixed and subjected to immunostaining. Pim-1L protein was detected by staining with anti-Flag antibody and Rhodamine-labeled secondary antibodies (red). Etk protein was detected by staining with polyclonal anti-Etk antibody and FITC-labeled secondary antibodies (green). The slides were analysed by laser scanning confocal microscopy. The colocalization of the two proteins was detected by the merge of the confocal images of both green and red. Yellow indicates the colocalization of Etk and Pim-1L.
Direct association of the p44 Pim-1 with Etk Y Xie et al appears to be essential for drug-induced p53-mediated apoptosis . We therefore examined whether the interaction between Etk and Pim-1L can compete with its association with p53. Figure 5e shows that the interaction between Etk and p53 was disrupted by Pim-1L but not by Pim-1LDP, suggesting a competition between the proline-rich domains of Pim-1L and p53 for binding to the SH3 domain of Etk. Taken together, our results suggest that Pim-1L may play a more prominent role in antiapoptosis signaling in response to chemotherapeutic drugs by competing with p53 for binding to Etk. The cells were then lysed and the lysates were subjected to immunoprecipitation. The association between Etk and Pim-1 in COS-1 cells was determined by immunoprecipitation with the anti-Etk antibody and followed by immunoblotting with anti-Flag antibody. The effects of Pim-1 on Etk kinase activity were examined by immunoprecipitation with anti-Etk and followed by immunoblotting with anti-phosphotyrosine (apY). In 22Rv1 cells, the reciprocal co-immunoprecipitations were carried out to detect the association of Etk with Pim-1. The levels of Etk or Pim-1 in the total cell lysates were monitored by immunoblotting with anti-T7 and anti-Flag, respectively. (b) The SH3 domain of Etk is required for binding to Pim-1L. T7-tagged Etk or Etk mutants were cotransfected with Flag-Pim-1L into COS-1 cells. Immunoprecipitation was performed with polyclonal anti-Etk antibody and followed by immunoblotting with anti-Flag antibody. The immunoblots of total cell lysates with anti-Flag and anti-T7 were included to monitor the protein levels of Pim1 and Etk in the total cell lysates. (c) Direct interaction between the SH3 domain of Etk and the proline-rich region of Pim-1L. The GST-pull-down experiments were carried out by incubation of the immobilized GST-SH3(Etk) fusion protein or the GST control with the cell lysates from 293T cells overexpressing Flag-Pim-1L, Pim-1LDP or Pim-1LPA mutants. The associated proteins were resolved by the SDS-PAGE and detected by immunoblotting with anti-Flag antibody (top). The same blot was stained with Coomassie blue to monitor the amount of the GST-SH3 fusion proteins bound to the glutathione beads (bottom). (d) Endogenous Etk is associated with Pim-1L in PCA cells. Lysates from LNCaP and PC3 cells were immunoprecipitated with polyclonal Pim-1 antibody or preimmune serum control, followed by immunoblotting with monoclonal anti-Etk antibody or anti-Pim-1 antibodies. The total cell lysates (TCL) from these cells were included to serve as the positive controls. (e) Effects of Pim-1 on endogenous Etk kinase activity. HUVEC or LNCaP cells were infected with the lentivirus encoding Flag-Pim1L, Pim-1LDP or vector alone. At 24 h postinfection, the cells were serum starved for 6 h (HUVEC) and 16 h (LNCaP), respectively. Immunoprecipitation was performed by using anti-Etk. Tyrosine phosphorylation of Etk and Stat3 was determined by immunoblotting with anti-phosphtyrosine (4G10) and antiphospho Stat3 Y705, respectively. The expression of Flag-Pim1L or Pim-1LDP produced by the respective lentivirus in COS-1 cells was determined by immunoblotting with anti-Flag antibody. (f) Effects of Pim-1 on Etk kinase activity by the in vitro kinase assay. COS-1 cells were transfected with the indicated plasmids. At 24 h post-transfection, the cells were serum starved for 16 h and then subjected to immunoprecipitation with anti-Etk. Subsequently, the in vitro kinase assay (IVK) was carried out by using GST-Gab1 as a substrate as described in the Materials and methods section. The amount of the substrate used in the IVK was determined by Commassie blue staining (CB). The Pim-1 expression level in the transfected cells was determined by immunoblotting with anti-Flag (bottom).
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To further demonstrate that endogenous Pim-1 indeed plays a role in the regulation of drug sensitivity in prostate cancer cells, we treated LNCaP cells with the lentiviral vector encoding the siRNA specific for Pim-1.
As shown in Figure 6a , the siRNA for Pim-1 completely abolished the expression of Pim-1L protein and inhibited the expression of Pim-1S protein by about 30%. The viability of LNCaP cell expressing the siRNA was Figure 5a . The cells were treated with 10-100 nM mitoxantrone for 48 h and the cell viability was determined as in Figure 5a . *Po0.01 compared with the vector control. (d) Etk mediates Pim-1L-induced resistance to mitoxantrone. LNCaP cell were infected with the lentiviruses as described in Figure 5b . The drug responses of these cells were determined as in Figure 5c . *Po0.01 compared with the vector control; **Po0.01 compared with Pim-1L alone. (e) Pim-1L disrupts the interaction between Etk and p53. LNCaP cells were transfected with the plasmids as indicated. The association of Etk with p53 was determined by immunoprecipitation with anti-p53 and followed by immunoblotting with anti-T7 antibody. The expression of p53, Etk or Pim-1 in these cells was monitored by immunoblotting with anti-p53, anti-T7 and anti-Flag antibody, respectively. Direct association of the p44 Pim-1 with Etk Y Xie et al significantly comprised when they were treated with doxorubicin or mitoxantrone. These data indicate that downregulation of Pim-1L sensitize prostate cancer cells to chemotherapeutic drugs.
Discussion
Increasing evidence suggests that Pim-1 plays an important role in prostate cancer development and progression. Most of the studies on Pim-1 have been focused on the 33 kDa isoform. In the present report, we have demonstrated the 44 kDa isoform Pim-1 (Pim-1L) is expressed in all prostate cancer cell lines tested and significantly upregulated in human prostate tumor specimens in comparison to the BPH controls. Although the alternative translation initiation site CUG in human pim-1 gene is not present in an optimal Kozak consensus context as its mouse counterpart, the 44 kDa Pim-1L is encoded efficiently and detectable in all human prostate cancer cell lines tested as well as human prostate tumor specimens. It is noteworthy that Pim-1L is expressed at the highest level in PC3 cells. The relative ratio between the levels of Pim-1L to Pim-1S is also highest in PC3 cells for both the endogenous Pim-1 and the ectopically expressed EST clones. At present, it is not clear whether the relatively high level of Pim-1L in PC3 cells is due to the increased stability of Pim-1L or the enhanced efficiency of usage of the alternative CUG translation initiation site. The PC3 cell line is known for its remarkable resistance to various apoptosis inducers. It remains to be tested whether the relatively high expression level of Pim-1L could count for it at least in part.
The Pim-1L contains three PXXP motifs in its unique N-terminal sequence, which can compete with the proline-rich motifs of p53 for binding to the SH3 domain of tyrosine kinase Etk. Our previous study showed that downregulation of Etk activity by p53 is necessary for DNA damage-induced apoptosis in LNCaP cells. Therefore, disruption of the p53 binding to Etk by Pim-1L leads to the activation of Etk tyrosine kinase activity and confers the resistance to chemotherapeutic drugs in prostate cancer cells. It is possible that such antagonist effect of Pim-1L against tumor suppressor p53 may also be important for the oncogenesis induced by the aberrant expression of the pim-1 gene in both human and mouse models. Pim-1L is primarily localized on the plasma membrane in LNCaP cells, possibly through its interaction with Etk. Given the different cellular localization of these two isoforms of Pim-1, it is conceivable that they may phosphorylate different protein substrates and play distinct roles in prostate cancer development and progression. The known potential substrates for the 33 kDa Pim-1S such as cdc25A, p100 and HP1 are primarily nuclear proteins. We demonstrated in this report that Pim-1L directly interacts with tyrosine kinase Etk on the plasma membrane and plays a more prominent role in antiapoptosis signaling in response to chemotherapeutic drugs in comparison to Pim-1S. In addition to binding to Etk and inducing activation of Etk kinase activity, localization of the Pim-1L on the plasma membrane may also allow it to phosphorylate some membrane or membrane-associated proteins, which are directly involved in drug resistance. Identification of these proteins in the future will provide new insights into the mechanisms by which Pim-1 exerts its antiapoptosis effects in prostate cancer cells.
Materials and methods

Plasmid constructs and antibodies
Two human EST clones in the pCMV-SPORT6 expression vector (GI: 18 514 371 and GI: 10 339 628) were obtained from ATCC. The full-length human 44 kDa Pim-1 cDNA (Genbank Accession number DQ022562) was amplified by PCR using the EST clones as the template. The PCR products were subcloned into the pcDNA3-based vector to replace the Flag-tagged murine p33 Pim-1 (kindly provided by Dr Hirano; Shirogane et al., 1999) by restriction digestion with EcoRI/XbaI. All human Pim-1 constructs contain the N-terminal Flag-tag. To generate the kinase-inactive Pim-1 mutant, the lysine residue at position 158 of Pim-1L was mutated to methionine via oligonucleotide-directed mutagenesis with the forward mutagenic primer 5 0 -GCCGGTGGCCATCATGCACGTGGAGA AGG-3 0 , and its reverse primer by using the Quickchange Mutagenesis Kit (Stratagene). The mutants containing deletion (Pim-1LDP in which the first 15 amino acids are deleted) or mutation (Pim-1LPA in which prolines 2, 5, 8 and 11 are substituted by alanines) of the PXXP motifs of human Pim-1L Direct association of the p44 Pim-1 with Etk Y Xie et al were also generated. All mutations were confirmed by sequencing. T7-tagged Etk and its mutants T7-EtkKQ were described previously (Qiu et al., 1998) . The polyclonal antibody against the Pim-1L was generated by immunizing the rabbits with the purified GST fusion protein containing the first 91 amino acids at the N-terminus of Pim-1L following the standard protocol. The monoclonal anti-Pim-1 antibody (cat# sc13513) was purchased from Santa Cruz.
Cell culture and transfection All cell lines (except for CWR-R1) used in this study were purchased from American Tissue Culture Collections. CWR-R1 cells were kindly provided by Dr CW Gregory (Gregory et al., 2001) . The 293T and COS-1 cells were maintained in DMEM supplemented with 10% fetal bovine serum. LNCaP and PC3 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum. 22Rv1 and CWR-R1 cells were maintained in RPMI1640 supplemented with 10% heatinactivated fetal bovine serum. Transfections were performed by using Fugene 6 (Roche), Lipofectamine 2000 (GIBCO/BRL) or the calcium phosphate precipitation method (Biological Mimetics Inc.) according to the manufacturer's instructions.
GST-pull-down assay GST fusion proteins were expressed and purified as described previously (Chen et al., 2001; Jiang et al., 2004) . Briefly, the GST fusion proteins were pulled down by glutathione beads at 41C for 1 h and then washed three times with the lysis buffer (Kim et al., 2002) . The immobilized GST fusion proteins were incubated with the lysates of 293T cells transfected with the Flag-tagged Pim-1 for 1 h at 41C. The beads were washed with the lysis buffer four times and then the protein complexes were loaded in 10% SDS-polyacrylamide gel electrophoresis (PAGE), followed by immunoblotting with anti-Flag antibody.
Immunoprecipitation and Western blot
The transfected cells were lysed in the buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mg/ml aprotinin, 1 mg/ml leupterin and 1 mM PMSF). Insoluble material was removed by centrifugation, and antibodies were added to lysates and incubated for 1-3 h at 41C. The immunocomplexes were collected by using protein A or protein G-sepharose beads, and the beads were then washed extensively for three times at 41C with the lysis buffer. Immunoblotting was performed as described previously (Kim et al., 2002) . Briefly, blots were incubated with primary antibodies, 1:5000 dilution of anti-T7 tag, 1:2000 dilution of anti-phosphotyrosine, 1:2000 dilution of anti-Flag tag, 1:100 dilution of anti-Pim1 at room temperature for 1 h, and followed by detection with horseradish peroxidaseconjugated secondary antibody.
In vitro kinase assays The Etk IVK assays were carried out as described previously . Briefly, the Etk immunoprecipitates were washed twice with the kinase buffer (50 mM Tris-HCl, pH 8.0, 10 mM MnCl 2 ) and then incubated at room temperature with kinase buffer containing 2 mg of GST-Gab1CT and 200 mM ATP. The reaction was terminated by adding the equal volume of 2 Â SDS sample buffer and boiling for 10 min. The reaction mixtures were separated by 10% SDS-PAGE. The tyrosine phosphorylation of Gab1CT was detected with anti-phosphotyrosine antibody (4G10).
Immunofluorescence and immunohistochemical staining and confocal microscopy LNCaP cells were seeded on coverslips and transfected with 0.5 mg DNA/10 5 cells by the Lipofectamine 2000 transfection reagent (GIBCO/BRL). At 48 h post-transfection, the cells were fixed in 3.7% paraformaldehyde for 15 min. Immunostaining was performed by incubating the slides with 1:200 dilution of anti-Flag monoclonal antibody (M2) for 45 min and/or with 1:200 dilution of anti-Etk for 1 h at room temperature, followed by incubation with the Rhodamineconjugated goat anti-mouse antibody and the FITC-conjugated goat anti-rabbit antibody for 45 min at room temperature. The slides were then washed and mounted with Vectashield (Vector Laboratories). The stained slides were examined by using an inverted microscope under a Â 60 oil-immersion objective and scanned with a laser confocal system. The human prostate tissue arrays containing 20 of paraffinembedded benign prostate tissue samples and 20 of prostate tumor tissues were purchased from Zymed. In all, 10 pairs of paraffin-embedded matched BPH and prostate tumor tissues were also included in our survey to facilitate the statistic analysis. The standard biotin-avidin complex immunohistochemistry was performed with anti-Pim-1L according to the protocol provided by the manufacturer (Vector Laboratories). The intensity of the staining was evaluated blindly and graded on a scale of 0 (negative) to 2 þ (strong positive) as reported previously (Imasato et al., 2000) . The extent of the positive staining in the BPH glands and tumor foci was classified as 0, 1-25, 26-50, 50-75 and 76-100% as described previously (Imasato et al., 2000) .
Drug-sensitivity assay
LNCaP cells were infected with the lentiviruses encoding the proteins or siRNA as indicated by using the protocol described previously . The siRNA target sequence of human pim-1 gene is GCAGGACAGTGCTTGATAC. We were able to achieve over 95% infection rate routinely as determined by expression of the GFP marker. At 48 h postinfection, the cells were seeded into the 96-well plates (3 Â 10 4 / well). Doxorubicin or mitoxantrone was added in the medium after 24 h. The effects of doxorubicin on the viability of cells were measured after 20-48 h by the WST-1 assay (Roche Molecular Biochemicals). The relative viability was expressed as the mean7s.d. of the triplicate for the drug-treated samples relative to the untreated controls. An aliquot of cells was lysed and followed by immunoblotting with anti-T7 or anti-Flag to monitor the transfection efficiency.
